Omeprazole versus Vonoprazan in Non-bismuth Quadruple Regimens for Eradication of Helicobacter Pylori: A rRandomized Controlled Trial

Efficacy of Omeprazole versus Vonoprazan in Non-bismuth Quadruple Regimen for Eradication of Helicobacter Pylori: A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410526786105

Enrollment

200

Registered

2024-10-16

Start date

2024-10-05

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System H. pylori

Interventions

Omeprazole

Vonoprazan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 years or more. Positive Stool antigen test (SAT).

Exclusion criteria

Exclusion criteria: Patients who refused to participate. Aged less than 18 years; Experienced H. pylori eradication therapy; Intake of any of the following medications within the last 6 weeks: antibiotics, anticoagulant, antacids including histamine (H2) receptor blockers and proton pump inhibitor (PPI), or nonsteroidal anti-inflammatory drugs; Patients with known allergy to any of the used drugs; Active gastrointestinal bleeding; Recent gastric surgery; Gastrointestinal malignancy; Pregnant or lactating women; patienst with hepatic or renal impairment.

Design outcomes

Primary

Measure	Time frame
eradication rate in each group.	—

Secondary

Measure	Time frame
side effects of used regimens.	—

Countries

Egypt

Contacts

Public ContactMuhammad Muhammad

Professor of Gastroenterology

muhammad2013@azhar.edu.edg+201113528652

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026